IELSG47MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas
Participants required:175 (130 patients with EMZL + 30 SMZL and 15 NMZL – enrolment completed)
Investigator responsible(s):C.Thieblemont, A. Conconi
Objective(s):The study aims to assess the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to explore its activity in SMZL and NMZL as an exploratory subset.

Home | Go to Studies